User menu

Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR)

Bibliographic reference Bruchfeld, Annette ; Schaier, Matthias ; Harper, Lorraine ; Jadoul, Michel ; Segelmark, Marten ; et. al. Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR).American Society of Nephrology (Atlanta, USA, du 05/11/2013 au 10/11/2013).
Permanent URL http://hdl.handle.net/2078.1/139233